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Background: The identification by CFTR mRNA studies of a new deep-intronic splicing mutation, c.870-1113_1110delGAAT, in one patient of
our series with mild CF symptoms and in three CF patients of an Italian study, led us to evaluate the mutation frequency and phenotype/genotype
correlations.
Methods: 266 patients with CF and related disorders and having at least one undetected mutation, were tested at the gDNA level in three French
reference laboratories.
Results: In total, the mutation was found in 13 unrelated patients (5% of those already carrying a mutation) plus 4 siblings, including one
homozygote and 12 heterozygotes having a severe CF mutation. The sweat test was positive in 10/14 documented cases, the diagnosis was
delayed after 20 years in 9/15 and pancreatic insufficiency was present in 5/16.
Conclusion: c.870-1113_1110delGAAT should be considered as CF-causing with phenotype variability and overall delayed diagnosis. Its
frequency highlights the potential of mRNA studies.
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More than 1800 mutations of the cystic fibrosis transmem-
brane conductance regulator (CFTR) gene have been reported
so far in patients with cystic fibrosis (CF) and CFTR-related
disorders (CFTR-RD) (www.genet.sickkids.on.ca/cftr/app),d by Elsevier B.V. All rights reserved.
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where the diagnostic criteria of CF cannot be unambiguously
established [1,2]. Still 1-5% of CF alleles remain unidentified
after comprehensive gene analyses in CF patients [1]. Part of
them may carry deep-intronic, splicing alterations, which can be
detected by messenger RNA (mRNA) studies only [3,4].
Implementation of mRNA studies in our laboratory practice led
to identification in an adult patient with a mild phenotype of a
4 bp deletion within intron 7 (previously 6b), named c.870-
1113_1110delGAAT (1002-1113_1110delGAAT) and causing
the inclusion of a cryptic exon in the mRNA [5]. As this
mutation had been independently described in three unrelated
Italian CF patients [6], we screened for it in a large number of
patients with various phenotypes through a French collaborative
study.Table 1
Phenotype and genotype data of patients found to carry the intron 7 c.870-1113_11
Patient
#
Gender Age at
diagnosis (y)
Current
age (y)
Pulmonary
symptoms
Pancreatic
status
Infertility
1 F 23 25 DB, Pa PS Nd
2 F NBS 4 None declared PS Na
3 M 8 Deceased DB PI Na
4 F 6 28 DB PI No
5 M 3 26 DB, Pa PI Nd
6 F 10 24 None declared PS Nd
7 F Childhood 28 DB PS No
8 F 31 51 DB, Pa and Sa
FEV1 24%
PS No
9 F 31 51 DB PS No
10 M 42 55 DB , Sa , H i ,
FEV1 50%
PS CBAVD
11 M 37 55 DB PI CBAVD
12 M 40 59 DB, Pa infection PI CBAVD
13 M 24 29 None declared PS No
14 F 64 70 DB , S a , M .
kansaii and M.
av ium , FEV1
77%
PS No
15 F 14 19 None declared PS Na
16 M 35 43 None declared Nd CBAVD
17 F Nd 28 DB PS Nd
CBAVD: congenital bilateral absence of vas deferens; CSD: chronic sinus disease; D
Hi: Haemophilus influenza; M: Mycobacterium; Na: not applicable; NBS: newb
aeruginosa; PI: pancreatic insufficiency; PS: pancreatic sufficiency; Sa: StaphylocoWe here provide evidence that c.870-1113_1110delGAAT is
a quite frequent CF mutation associated with an overall
moderate phenotype and delayed diagnosis. Such a result
emphasizes the importance of including the systematic search
for mRNA defects in clinical practice.
2. Patients and methods
2.1. Mutation nomenclature
Mutation names are given according to Human Genome
Variation Society (HGVS) nomenclature, with traditional names
in brackets at their first occurrence (www.genet.sickkids.on.ca/
cftr). Exon numbering also follows HGVS rules: for instance, exon
6b has become exon 7.10delGAAT mutation.
Other Sweat test
(mmol/L)
Final
diagnosis
2nd allele Geographic origin
of the intron
7 mutation
CSD 35 C F T R -
RD
p.Phe508del France
None declared 83 CF p.[Phe508del;
Leu467Phe]
France (Corsica)
Failure to thrive
(−2SD)
Deceased at 14y
40-59 CF p.Phe508del France
Sister of patient
#3
37-58 CF p.Phe508del France
100 CF p.Gly542X Nd
Sister of patient
#5
≥60 CF p.Gly542X Nd
≥60 CF p.Phe508del Nd
≥60 CF p.Gly542X France (Center)
Sister of patient
#8; lung
transplantation at
43y
≥60 CF p.Gly542X France (Center)
Brother of patient
#8; diabetes
Nd CF p.Gly542X France (Center)
Nasal polyposis ≥60 CF p.Arg553X France (Corsica)
Diabetes; high
blood pressure;
kidney lithiasis
80-83 CF p.Gly542X Italy
Acute
pancreatitis
Nd C F T R -
RD
c . 8 7 0 -
1113_1110
delGAAT
France
70-83 CF p.Phe508del France
Chronic
pancreatitis
60, 105 CF p.Arg117Cys France
Nd C F T R -
RD
Undetected Nd
b40 C F T R -
RD
Undetected France
B: disseminated bronchiectasis; FEV1: forced expiratory volume in one second;
orn screening; Nd: not documented; NP: nasal polyposis; Pa: Pseudomonas
ccus aureus.
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Written informed consent was obtained from all the
individuals studied. After complete scanning of the CFTR
coding sequence including search for large rearrangements on
genomic DNA (gDNA) [7], nasal epithelial cells were collected
by gently brushing the inferior turbinates of one or both nostrils
under endoscopic view, suspended in RNAlater® (Qiagen), and
sent to the laboratory at room temperature. The mRNA study
included five healthy subjects with no CF or CFTR-RD
mutation after comprehensive analysis, and the proband, a
25y-old woman of French origin (patient #1, Table 1),
presenting with a mild pulmonary phenotype and who was
heterozygous for c.1521_1523delCTT, p.Phe508del (F508del).2.3. Strategy for identification of mRNA defects by mRNA analysis
PCR amplification of CFTR cDNA was performed in eight
overlapping fragments. Aberrant transcripts were identified in
two steps (detailed protocol available upon request): 1) sizing
the PCR products on acrylamide gel, followed by sequencing
and high pressure liquid phase chromatography (HPLC)
analysis in non denaturing conditions (Wave® System,
Transgenomic) for the detection of minor fractions of aberrant
transcripts; 2) collection and sequencing of the abnormal
fractions observed. Mutations found at the cDNA level were
further investigated by gDNA sequencing.2.4. Patients and methods for gDNA screening for
c.870-1113_1110delGAAT
A series of 266 patients referred to three French reference
laboratories (Cochin, Créteil and Montpellier) were selected for
testing the c.870-1113_1110delGAAT splicing mutation on
gDNA: according to consensus criteria [1,8], 73 had CF (58
with one CFmutation, 15 with nomutation identified), 24 clinical
features compatible with CF but without a documented positive
sweat test (21 with one CF mutation) and 169 had a CFTR-RD
(139 with one CF mutation or a mutation that result in a CFTR-
RD such as the T5 splicing variant c.1210-12T[5]—[1]),
including 58 disseminated bronchiectasis (DB), 71 congenital97b
afte
a
Figure 1. cDNA pattern of the fragment encompassing exons 5 to 9, observed in the p
97 bp insertion between exon 7 and 8. 1a. HPLC analysis. The patterns (plain lines
corresponding to the abnormal transcript are indicated by a plain arrow and heterodup
the corresponding fractions. 1b. Acrylamide gel. N: normal control; P: patient.bilateral absence of vas deferens (CBAVD) and 40 idiopathic
pancreatitis.
The mutation was screened for by sequencing using the
following primers: forward 5′-GGGTTGGGCACATTAAACTC-
3′ and reverse 5′-CTGGCATTTGGGCATTAGTT-3′.
3. Results
3.1. cDNA analysis of the proband
Patient #1, p.Phe508del heterozygous, had a longer cDNA
fragment besides the normal one covering exons 5–9 (Fig. 1).
Sequencing of this minor fraction collected by HPLC identified
an insertion of 97 bp of intron 7 between exons 7 and 8, deleted
of 4 bp (GAAT). The 4 bp deletion was confirmed on gDNA as
c.870-1113_1110delGAAT. This mutation has been character-
ized at the functional level by another team, the resulting
abnormal mRNA being predicted to cause the insertion of nine
amino-acids followed by a stop codon [6].
3.2. Screening for c.870-1113_1110delGAAT in gDNA
Among 266 unrelated patients screened, we identified one
homozygote (as confirmed by semi-quantitative multiplex PCR
[7]) and 11 heterozygotes who were referred from the different
phenotypic groups studied. Four affected siblings of three patients
were then identified with the same genotypes (Table 1). A total of
17 patients carrying the mutation were thus identified, including
the proband (#1). Compound heterozygosity was confirmed in all
cases. Themutations in trans of c.870-1113_1110delGAATwere
mostly frequent severe mutations: p.Phe508del (n=5 families);
c.1624GNT, p.Gly542X (G542X) (n = 3 families); and
c.1657CNT, p.Arg553X (R553X) (n=1 family).
3.3. Clinical outcome in the patients with
c.870-1113_1110delGAAT
One child was diagnosed through newborn screening and is
still healthy. The sixteen other patients were diagnosed on
clinical signs or because of an affected sibling. Among them,
age at diagnosis ranged from 3 to 64 years. Six were diagnosed
before 15 years: one child (#3) had a severe phenotype withp insertion
r exon 7
N P
b 
atient carrying c.870-1113_1110delGAAT (1002-1113_1110delGAAT), with a
) are superimposed on normal ones (dotted lines). The homoduplex molecules
lexes by a dotted arrow. They were characterized as such by sequence analysis of
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died at age 14; the five others, including patient #3's sister, are
now adults. Nine patients were diagnosed after 20 years, with a
mean age at diagnosis of 36 years.
Eleven patients were diagnosed on pulmonary symptoms,
two on CBAVD and two on pancreatitis. PI was present in five
of 16 documented cases.
Based on sweat chloride values ≥60 mmol/L, the diagnosis
of CF was initially established or further confirmed in 10 of 14
documented cases. Two patients had borderline values (40–
59 mmol/L) but had a clinical phenotype of classical CF with PI
(#3 and 4) and two others had a negative sweat test (b40 mmol/
L) [8]. The sweat test was not documented or performed in three
patients having a mild phenotype, all being lost for follow-up.
The c.870-1113_1110delGAAT homozygous patient (#13)
was diagnosed in adulthood, presented with acute pancreatitis,
had no respiratory symptom and was fertile. No sweat test was
performed.
4. Discussion
4.1. A recurrent splicing mutation in intron 7
The c.870-1113_1110delGAAT mutation was initially iden-
tified in a patient having a mild phenotype and a normal sweat
test, and in three unrelated Italian patients having classical CF, the
four of them carrying a severe CF mutation in trans [5,6]. The
finding of this mutation in our series helped solve diagnosis in a
number of families studied in the early 90s. Some patients were
unfortunately lost for follow-up and detailed phenotypic data
were not available. Based on genotype–phenotype correlations in
17 patients, we here document that compound heterozygosity for
c.870-1113_1110delGAAT and a severe CF mutation is
associated with variable phenotypes, mostly classical CF with a
delayed diagnosis. Phenotype variability may be related to the
level of aberrant mRNA. Indeed, although our mRNA assay was
not quantitative, the abnormal mRNA in patient #1 seemed to
correspond to a minor fraction of total mRNA (Fig. 1), in keeping
with the mild phenotype, whereas it appeared more balanced with
the normal mRNA fraction in the patients described by Faa et al.
[6]. Indeed, the authors showed that decrease of the splicing factor
SRp75 expression corrected the abnormal splicing pattern caused
by this mutation. Variations in such splicing factors could explain
inter and intra-familial phenotype variability, as documented in
our series, and be considered as CF genetic modifiers.
The c.870-1113_1110delGAAT mutation should thus be
considered as causing CF (Class A, according to clinical
classification of CFTR sequence variations [1,2]) but care
should be taken with genetic counseling, in particular for
prenatal diagnosis, with respect to the delayed diagnosis.
Considering its frequency among unrelated patients with
possible CF or CFTR-RD and already carrying a mutation in
our series, including the proband (11/219, 5%), the mutation
should be part of the second-level CFTR analysis at the gDNA
level.4.2. Implementation of CFTR mRNA analyses in the clinical
practice
The protocol for mRNA analysis set up in our diagnostic
laboratory complements the routine analysis on gDNA; it is
simple and reproducible. It allows identification of heretofore
undetected deep-intronic splicing defects, whose contribution
could even be more important in atypical presentations or
CFTR-RD than in classical CF. In addition, a number of known
CFTR mutations may have a splicing effect that can only be
demonstrated by investigating mRNA [9]. This is of the utmost
importance as emerging new generation sequencing procedures
may uncover many unclassified variants, some being potentially
deleterious. Overall, this emphasizes the importance of
implementing CFTR mRNA analysis in clinical practice.
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